Total Payments
$6,362
2024 Payments
$2,049
Companies
56
Transactions
265
Medicare Patients
11,242
Medicare Billing
$2.6M
Payment Breakdown by Category
Food & Beverage$6,040 (94.9%)
Education$321.93 (5.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,040 | 261 | 94.9% |
| Education | $321.93 | 4 | 5.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $600.47 | 30 | $0 (2024) |
| PFIZER INC. | $461.60 | 30 | $0 (2024) |
| Astellas Pharma US Inc | $458.77 | 10 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $426.41 | 6 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $292.39 | 13 | $0 (2024) |
| Incyte Corporation | $256.07 | 12 | $0 (2024) |
| Lilly USA, LLC | $247.90 | 4 | $0 (2022) |
| Genentech USA, Inc. | $238.69 | 6 | $0 (2024) |
| SERVIER PHARMACEUTICALS LLC | $216.62 | 10 | $0 (2024) |
| Daiichi Sankyo Inc. | $216.16 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,049 | 97 | Novartis Pharmaceuticals Corporation ($277.78) |
| 2023 | $2,612 | 113 | Astellas Pharma US Inc ($402.39) |
| 2022 | $930.93 | 45 | Lilly USA, LLC ($147.90) |
| 2021 | $51.51 | 3 | Incyte Corporation ($39.05) |
| 2019 | $12.91 | 1 | AstraZeneca Pharmaceuticals LP ($12.91) |
| 2017 | $705.19 | 6 | E.R. Squibb & Sons, L.L.C. ($369.16) |
All Payment Transactions
265 individual payment records from CMS Open Payments — Page 2 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/22/2024 | Octapharma USA, Inc. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: IMMUNOLOGY | ||||||
| 07/18/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $20.98 | General |
| Category: Oncology | ||||||
| 07/17/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO | Food and Beverage | In-kind items and services | $8.05 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 07/15/2024 | PFIZER INC. | BOSULIF (Drug), BESPONSA | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 07/11/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $27.13 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $21.74 | General |
| Category: Iron Deficiency Anemia | ||||||
| 07/10/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $20.79 | General |
| 07/09/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $7.07 | General |
| Category: ONCOLOGY | ||||||
| 06/25/2024 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $29.64 | General |
| Category: Interventional Oncology | ||||||
| 06/21/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $28.25 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY | Food and Beverage | In-kind items and services | $30.95 | General |
| Category: Oncology | ||||||
| 06/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $29.84 | General |
| Category: Oncology | ||||||
| 06/18/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $26.64 | General |
| Category: Oncology | ||||||
| 06/18/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $7.15 | General |
| Category: ONCOLOGY | ||||||
| 06/17/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $11.58 | General |
| Category: Immunology | ||||||
| 06/17/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $0.77 | General |
| Category: Immunology | ||||||
| 06/11/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $31.89 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 06/11/2024 | Octapharma USA, Inc. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: IMMUNOLOGY | ||||||
| 06/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $25.36 | General |
| Category: Oncology | ||||||
| 06/05/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: Oncology | ||||||
| 05/30/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $23.17 | General |
| Category: Hematology/Oncology | ||||||
| 05/30/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Oncology | ||||||
| 05/28/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug), IDHIFA | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: Oncology | ||||||
| 05/24/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 90 | 8,458 | 218,117 | $6.5M | $2.4M |
| 2022 | 43 | 2,588 | 25,945 | $579,891 | $200,710 |
| 2021 | 7 | 182 | 185 | $58,919 | $18,112 |
| 2020 | 1 | 14 | 14 | $5,108 | $1,526 |
Total Patients
11,242
Total Services
244,261
Medicare Billing
$2.6M
Procedure Codes
145
All Medicare Procedures & Services
145 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 23 | 23,120 | $1.3M | $547,159 | 40.8% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 28 | 11,600 | $1.3M | $504,645 | 39.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 74 | 12,000 | $342,600 | $214,958 | 62.7% |
| J1930 | Injection, lanreotide, 1 mg | Office | 2023 | 12 | 2,880 | $268,819 | $130,976 | 48.7% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 12 | 3,420 | $299,934 | $129,313 | 43.1% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 32 | 2,710 | $166,475 | $97,705 | 58.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 627 | 802 | $132,330 | $71,461 | 54.0% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 89 | 75,750 | $227,250 | $65,615 | 28.9% |
| Q5126 | Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | Office | 2023 | 11 | 1,100 | $81,400 | $60,680 | 74.5% |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Office | 2023 | 12 | 5,900 | $92,984 | $57,955 | 62.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 228 | 540 | $194,400 | $52,213 | 26.9% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 23 | 432 | $157,680 | $36,379 | 23.1% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 16 | 1,670 | $203,506 | $34,535 | 17.0% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 17 | 348 | $234,552 | $32,484 | 13.8% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 52 | 1,271 | $127,100 | $22,864 | 18.0% |
| Q5112 | Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg | Office | 2023 | 11 | 501 | $72,224 | $21,665 | 30.0% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 54 | 13,910 | $73,445 | $18,982 | 25.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 114 | 149 | $32,780 | $18,804 | 57.4% |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | Office | 2023 | 22 | 3,600 | $36,756 | $16,465 | 44.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 184 | 771 | $61,680 | $16,334 | 26.5% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 40 | 2,500 | $55,500 | $15,778 | 28.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 1,066 | 1,928 | $69,408 | $14,584 | 21.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 1,012 | 1,695 | $15,255 | $14,238 | 93.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 121 | 121 | $25,410 | $14,175 | 55.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 796 | 1,368 | $39,426 | $14,083 | 35.7% |
About Dr. Jong An, DO
Dr. Jong An, DO is a Hematology & Oncology healthcare provider based in Lynchburg, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2007. The National Provider Identifier (NPI) number assigned to this provider is 1043419096.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jong An, DO has received a total of $6,362 in payments from pharmaceutical and medical device companies, with $2,049 received in 2024. These payments were reported across 265 transactions from 56 companies. The most common payment nature is "Food and Beverage" ($6,040).
As a Medicare-enrolled provider, An has provided services to 11,242 Medicare beneficiaries, totaling 244,261 services with total Medicare billing of $2.6M. Data is available for 4 years (2020–2023), covering 145 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Lynchburg, VA
- Active Since 07/11/2007
- Last Updated 01/27/2026
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1043419096
Products in Payments
- OPDIVO (Biological) $426.41
- Tibsovo (Drug) $196.01
- KISQALI (Drug) $194.41
- Lenvima (Drug) $168.08
- JAKAFI (Drug) $153.45
- PROVENGE (Drug) $146.24
- CYRAMZA (Drug) $142.86
- JEVTANA (Drug) $135.15
- TECENTRIQ (Biological) $123.73
- BOSULIF (Drug) $121.36
- INJECTAFER (Drug) $119.58
- KEYTRUDA (Biological) $119.21
- ADVATE (Biological) $112.30
- clonoSEQ (Device) $112.17
- IBRANCE (Drug) $107.86
- Nubeqa (Drug) $103.58
- Stivarga (Drug) $99.68
- Enhertu (Drug) $96.58
- LIBTAYO (Biological) $95.24
- INLYTA (Drug) $84.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Lynchburg
Nicholette Erickson, Md, MD
Hematology & Oncology — Payments: $6,385
Hematology & Oncology $6,385
Amir Khan, M.d, M.D
Hematology & Oncology — Payments: $789.22
Hematology & Oncology $789.22
Dr. Emaculate Tebit, M.d, M.D
Hematology & Oncology — Payments: $29.86
Hematology & Oncology $29.86
Dr. Mahmood Rasheed, M.d, M.D
Hematology & Oncology — Payments: $25.52
Hematology & Oncology $25.52
Pooja Mehra
Hematology & Oncology
Hematology & Oncology